Selitsky, Sara R.
Marron, David
Hollern, Daniel
Mose, Lisle E.
Hoadley, Katherine A.
Jones, Corbin
Parker, Joel S.
Dittmer, Dirk P.
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Funding for this research was provided by:
National Institutes of Health (U24-CA143848, 2-P01-CA019014-38)
Article History
Received: 13 March 2019
Accepted: 10 January 2020
First Online: 28 January 2020
Ethics approval and consent to participate
: <b>Cell lines</b>These cell lines were acquired in 2001–2004 before statements of approval were in use.<b>Human Subjects</b>Tumor tissue, adjacent normal tissue, and normal whole blood samples were obtained from patients at contributing centers with informed consent according to their local Institutional Review Boards (IRBs, see below). Biospecimens were centrally processed and DNA, RNA and protein were distributed to TCGA analysis centers. TCGA Project Management has collected necessary human subjects documentation to ensure the project complies with 45-CFR-46 (the “Common Rule”). The program has obtained documentation from every contributing clinical site to verify that IRB approval has been obtained to participate in TCGA. Such documented approval may include one or more of the following: UnorderedList removed
: Not applicable
: The authors declare that they have no competing interests.